Skip to main content
. 2011 Sep 23;16(10):1413–1421. doi: 10.1634/theoncologist.2011-0164

Figure 1.

Figure 1.

Gonadotropin-releasing hormone (GnRH)–gonadotropin axis. The proposed mechanism of GnRH analogs (goserelin, triptorelin) in epithelial ovarian cancer is thought to be desensitization or downregulation of GnRH receptors in the pituitary, resulting in a decline in gonadotropin secretion and subsequent reduction in gonadal steroids including androgens.